icon
icon
icon
icon
$300 Off
$300 Off

News /

Articles /

Becton Dickinson Surges to 20th in Trading Volume with $2.325 Billion Turnover Despite 18.13% Stock Price Decline

Market BriefThursday, May 1, 2025 8:07 pm ET
1min read

On May 1, 2025, Becton Dickinson (BDX) saw a significant surge in trading volume, with a turnover of $2.325 billion, marking a 310.18% increase from the previous day. This substantial rise placed bdx at the 20th position in terms of trading volume for the day. However, the stock price experienced a decline of 18.13%.

Becton Dickinson reported its second-quarter fiscal 2025 financial results, with revenue reaching $5.3 billion, reflecting a 4.5% increase year-over-year. The company's earnings per share (EPS) stood at $1.07 on a GAAP basis and $3.35 on an adjusted basis. The Medical segment and geographic performances continued to drive the company's overall topline growth.

During the earnings call, Becton Dickinson highlighted that its EPS of $3.35 exceeded the forecast of $3.28 by 2.1%. However, the reported revenue of $5.27 billion fell short of expectations by approximately 1.5%. The company's profits for the quarter were $308 million, equating to $1.07 per share on sales of $5.27 billion. Despite a 4.5% increase in sales, the company recorded a 42.6% decline in bottom-line performance.

Becton Dickinson adjusted its guidance for the fiscal year 2025 to account for the potential impact of tariffs announced by the Trump Administration. The company now expects revenues to range between $21.8 billion and $21.9 billion, reflecting updated organic revenue growth guidance of 3% to 3.5%. Before the tariff impact, the company projects adjusted diluted EPS to be in line with its previous guidance of $14.30 to $14.60. The estimated tariff impact for the fiscal year is approximately 25¢, resulting in a projected EPS range of $14.06 to $14.34.

Tom Polen, BD's chair, president, and CEO, commented on the company's performance, stating that despite a challenging operating environment, the second-quarter results demonstrated the strength of BD's business model. The company's bd Excellence operating system continues to drive margin expansion and investment in commercial organization and innovation. Polen expressed confidence in BD's ability to accelerate growth as markets recover and navigate the current macro environment, leveraging its scale as the largest U.S. manufacturer of medical devices for long-term value creation.

Comments

Add a public comment...
Post
User avatar and name identifying the post author
Fluffy-Belt1325
05/02
BD's margin expansion is 🔥. Tariffs might sting, but their guidance still looks solid. Holding for long-term gains here.
0
Reply
User avatar and name identifying the post author
Terrible_Onions
05/02
@Fluffy-Belt1325 I had BDX once, sold too early. Regretted it when it started climbing. FOMO hits hard when seeing gains like these.
0
Reply
User avatar and name identifying the post author
jhs0108
05/02
@Fluffy-Belt1325 How long you planning to hold BDX? Curious if you're thinking years or just riding the current trend.
0
Reply
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
You Can Understand News Better with AI.
Whats the News impact on stock market?
Its impact is
fork
logo
AInvest
Aime Coplilot
Invest Smarter With AI Power.
Open App